<DOC>
	<DOCNO>NCT02837445</DOCNO>
	<brief_summary>The purpose double blind randomize study evaluation safety efficacy Moderato System . The Moderato pacemaker indicate patient require dual chamber pacemaker also hypertension , order reduce blood pressure .</brief_summary>
	<brief_title>Moderato System : A Double-Blind Randomized Trial</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Bradycardia</mesh_term>
	<mesh_term>Atrioventricular Block</mesh_term>
	<mesh_term>Coronary Vasospasm</mesh_term>
	<criteria>Requirement dual chamber pacemaker . Stable ( least 1 month ) hypertension treatment least 1 antihypertensive drug , anticipate maintain least 7 month . Average day time ( 7AM10PM ) ambulatory systolic blood pressure ≥ 130 mmHg office blood pressure ≥140 mmHg . Subject live proximity study center , permit compliance study visit least 7 month . Known secondary cause HTN . Average ambulatory office systolic BP &gt; 195 mmHg . Permanent atrial fibrillation . History significant paroxysmal atrial fibrillation/flutter burden ( define &gt; 25 % beat ) . Cardiac ejection fraction &lt; 50 % . Symptoms heart failure , NYHA Class II great . Hypertrophic cardiomyopathy , restrictive cardiomyopathy interventricular septal thickness ≥ 15 mm . Subject dialysis . Subject estimate Glomerular Filtration Rate &lt; 30 ml/min/1.73 m² Prior neurological event ( stroke TIA ) within past year event prior time result residual neurologic deficit . Carotid artery disease . Known autonomic dysfunction . History clinically significant uncontrolled ventricular tachyarrhythmia experience sudden death . Previous active devicebased treatment HTN . Existing implant , pacemaker need replace . Subject possibility become pregnant unwilling contraception study . Subject unwilling provide Informed Consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>